First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

Bookmark and Share
Published: 22 Oct 2018
Views: 787
Prof Barbara Burtness - Yale University School of Medicine and Yale Cancer Center New Haven, USA

Prof Barbara Burtness speaks at a conference session at ESMO 2018 in Munich about results from KEYNOTE-048, a phase 3 study of first-line pembrolizumab R/M HNSCC.

For more on these results, watch her interview with ecancer.